Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
Humam Emad Rajha, Richard Shamoon, Ameer Almeshagbeh, Samah Masry, Fadel Alqatati, Baha H Abuajameia, Abdulqadir J Nashwan · 2026
Read Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis by Humam Emad Rajha, Richard Shamoon, Ameer Almeshagbeh, Samah Masry, Fadel Alqatati, Baha H Abuajameia, Abdulqadir J Nashwan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13638482.txt.
Description
Humam Emad Rajha and six colleagues published a systematic review and meta-analysis in 2026 on iron chelator drugs in chronic kidney disease. People with kidney disease often build up excess iron from transfusions and iron treatment, and the drugs that remove iron are well studied in other settings but not in this one.
The authors pooled eleven studies covering 206 patients in total. Chelation lowered ferritin, transferrin, and serum iron, and hemoglobin rose, while stomach and bowel side effects were common and serious events were rare. Because the studies were small and varied a lot, the authors say larger trials are needed before routine use.
Catalog record
| CREATOR | Humam Emad Rajha, Richard Shamoon, Ameer Almeshagbeh, Samah Masry, Fadel Alqatati, Baha H Abuajameia, Abdulqadir J Nashwan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42181 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |